Aminian A, Al-Kurd A, Wilson R, et al. - Researchers aimed at determining if bariatric surgery could aid in lowering the incidence of major adverse liver outcomes and major adverse cardiovascular events (MACE) in patients with obesity and biopsy-proven fibrotic nonalcoholic steatohepatitis (NASH) without cirrhosis.

• In the SPLENDOR (Surgical Procedures and Long-term Effectiveness in NASH Disease and Obesity Risk) study, researchers identified a total of 1,158 adult patients with obesity who fulfilled enrollment criteria for this study, including confirmed histological diagnosis of NASH and presence of liver fibrosis (histological stages 1-3).

• Of these patients, 650 patients underwent bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) and 508 patients received nonsurgical care.

• Outcomes revealed a significant correlation of undergoing bariatric surgery with a lower risk of major adverse liver outcomes (adjusted absolute 10-year risk difference of 12.4%) and major adverse cardiovascular events (adjusted absolute 10-year risk difference of 13.9%).